![Benjamin Yerxa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benjamin Yerxa
Director/Board Member at CLEARSIDE BIOMEDICAL, INC.
Net worth: 25 140 $ as of 2024-05-30
Benjamin Yerxa active positions
Companies | Position | Start | End |
---|---|---|---|
CLEARSIDE BIOMEDICAL, INC. | Director/Board Member | 2022-03-02 | - |
Independent Dir/Board Member | 2022-03-02 | - | |
The North Carolina Biotechnology Center
![]() The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 2010-10-31 | - |
SparingVision SAS
![]() SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Director/Board Member | - | - |
Vedere Bio II, Inc.
![]() Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Director/Board Member | - | - |
RainBio, Inc.
![]() RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Chairman | - | - |
Director/Board Member | - | - | |
Opus Genetics, Inc.
![]() Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Chief Executive Officer | 2022-06-30 | - |
Founder | 2021-01-31 | - | |
President | 2021-01-31 | 2022-06-30 | |
Nacuity Pharmaceuticals, Inc.
![]() Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Director/Board Member | - | - |
Career history of Benjamin Yerxa
Former positions of Benjamin Yerxa
Companies | Position | Start | End |
---|---|---|---|
Retinal Degeneration Fund | Chief Executive Officer | 2018-09-30 | 2022-06-30 |
The Foundation Fighting Blindness, Inc.
![]() The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Chief Executive Officer | 2017-10-16 | 2022-06-30 |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Benjamin Yerxa
University of California, Irvine | Doctorate Degree |
University of California San Diego | Undergraduate Degree |
Statistics
International
United States | 14 |
United Kingdom | 2 |
France | 2 |
Operational
Director/Board Member | 6 |
Chief Tech/Sci/R&D Officer | 4 |
Chief Executive Officer | 3 |
Sectoral
Health Technology | 9 |
Consumer Services | 3 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CLEARSIDE BIOMEDICAL, INC. | Health Technology |
Private companies | 12 |
---|---|
Inspire Pharmaceuticals, Inc.
![]() Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Liquidia Technologies, Inc.
![]() Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
The North Carolina Biotechnology Center
![]() The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Technology Services |
The Foundation Fighting Blindness, Inc.
![]() The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Commercial Services |
Burroughs Wellcome | |
Envisia Therapeutics, Inc.
![]() Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Nacuity Pharmaceuticals, Inc.
![]() Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Health Technology |
SparingVision SAS
![]() SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
Retinal Degeneration Fund | |
RainBio, Inc.
![]() RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Health Technology |
Vedere Bio II, Inc.
![]() Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
Opus Genetics, Inc.
![]() Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
- Stock Market
- Insiders
- Benjamin Yerxa
- Experience